Literature DB >> 5329617

Controlled sequential trials of carbamazepine in trigeminal neuralgia.

B W Rockliff, E H Davis.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1966        PMID: 5329617     DOI: 10.1001/archneur.1966.00470140019003

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


× No keyword cloud information.
  31 in total

Review 1.  Topiramate versus carbamazepine for the treatment of classical trigeminal neuralgia: a meta-analysis.

Authors:  Qiang-Ping Wang; Min Bai
Journal:  CNS Drugs       Date:  2011-10-01       Impact factor: 5.749

2.  Medical treatment of trigeminal neuralgia.

Authors:  J C Ramseyer
Journal:  Calif Med       Date:  1971-09

3.  [Not Available].

Authors:  U Thoden
Journal:  Schmerz       Date:  1992-03       Impact factor: 1.107

Review 4.  Pain Management in Multiple Sclerosis: a Review of Available Treatment Options.

Authors:  Talal Aboud; Nathaniel M Schuster
Journal:  Curr Treat Options Neurol       Date:  2019-11-27       Impact factor: 3.598

5.  Paroxysmal choreoathetosis after head injury.

Authors:  M E Drake; R D Jackson; C A Miller
Journal:  J Neurol Neurosurg Psychiatry       Date:  1986-07       Impact factor: 10.154

Review 6.  The side-effects of carbamazepine.

Authors:  J J Gayford; T H Redpath
Journal:  Proc R Soc Med       Date:  1969-06

7.  Oxcarbazepine: a new drug in the management of intractable trigeminal neuralgia.

Authors:  J M Zakrzewska; P N Patsalos
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-04       Impact factor: 10.154

8.  Treatment options in trigeminal neuralgia.

Authors:  Mark Obermann
Journal:  Ther Adv Neurol Disord       Date:  2010-03       Impact factor: 6.570

9.  Analysis of carbamazepine actions in hippocampal slices of the rat.

Authors:  T W Hood; J Siegfried; H L Haas
Journal:  Cell Mol Neurobiol       Date:  1983-09       Impact factor: 5.046

10.  [Pain therapy in herpes zoster and post-zoster neuralgia.].

Authors:  T Zenz; M Zenz; M Tryba
Journal:  Schmerz       Date:  1994-03       Impact factor: 1.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.